458 related articles for article (PubMed ID: 19500528)
1. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.
Jones RN; Kohno S; Ono Y; Ross JE; Yanagihara K
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):191-201. PubMed ID: 19500528
[TBL] [Abstract][Full Text] [Related]
2. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
3. Linezolid surveillance program results for 2008 (LEADER Program for 2008).
Farrell DJ; Mendes RE; Ross JE; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):392-403. PubMed ID: 19913682
[TBL] [Abstract][Full Text] [Related]
4. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
5. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
6. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
7. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
8. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
Ross JE; Fritsche TR; Sader HS; Jones RN
Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
[TBL] [Abstract][Full Text] [Related]
9. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
10. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
[TBL] [Abstract][Full Text] [Related]
11. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
[TBL] [Abstract][Full Text] [Related]
12. United States resistance surveillance results for linezolid (LEADER Program for 2007).
Jones RN; Ross JE; Castanheira M; Mendes RE
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
14. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):54-61. PubMed ID: 22704791
[TBL] [Abstract][Full Text] [Related]
15. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
Draghi DC; Sheehan DJ; Hogan P; Sahm DF
Antimicrob Agents Chemother; 2005 Dec; 49(12):5024-32. PubMed ID: 16304168
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of linezolid resistance in Germany, 2001-2002.
Brauers J; Kresken M; Hafner D; Shah PM;
Clin Microbiol Infect; 2005 Jan; 11(1):39-46. PubMed ID: 15649302
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
